New drug combo tested for Tough-to-Treat ovarian cancer
NCT ID NCT02867956
Summary
This study tested whether adding a new drug called apatinib to a standard chemotherapy (etoposide) could help control advanced ovarian cancer that had stopped responding to platinum-based treatments. It involved 35 women to see if the combination was effective and safe. The goal was to see if this approach could shrink tumors and delay cancer growth in patients with limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.